English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Because of the potentially high mortality rate (6.5%) associated with bortezomib‐induced lung disease ( BILD ) in  J apanese patients with relapsed or refractory multiple myeloma, we evaluated the incidence, mortality and clinical features of  BILD  in a  J apanese population. This study was conducted under the Risk Minimization Action Plan ( RMAP ), which was collaboratively developed by the pharmaceutical industry and public health authority. The  RMAP  consisted of an intensive dissemination of risk information and a recommended countermeasure to health‐care professionals. All patients treated with bortezomib were consecutively registered in the study within 1 year and monitored for emerging  BILD . Of the 1010 patients registered, 45 (4.5%) developed  BILD , 5 (0.50%) of whom had fatal cases. The median time to  BILD  onset from the first bortezomib dose was 14.5 days, and most of the patients responded well to corticosteroid therapy. A retrospective review by the Lung Injury Medical Expert Panel revealed that the types with capillary leak syndrome and hypoxia without infiltrative shadows were uniquely and frequently observed in patients with  BILD  compared with those with conditions associated with other molecular‐targeted anticancer drugs. The incidence rate of  BILD  in  J apan remains high compared with that reported in other countries, but the incidence and mortality rates are lower than expected before the introduction of bortezomib in  J apan. This study describes the radiographic pattern and clinical characterization of  BILD  in the  J apanese population. The  RMAP  seemed clinically effective in minimizing the  BILD  risk among our  J apanese population.

Bortezomib therapy‐related lung disease in J apanese patients with multiple myeloma: Incidence, mortality and clinical characterization